Summary In the present study we 
Breast cancer affects 1 in 12 women in the UK and accounts for 18% of female malignant disease worldwide. Of those who present with apparently operable disease, more than half will die from metastatic disease. Understanding the biological mechanisms underlying the metastatic process is therefore of major importance in the hope that such understanding will lead to the evolution of new therapeutic strategies.
Metastasis requires that the disseminating cell disengages from its primary site, migrates and adheres at a distant site -all processes dependent on regulated-dysregulated cellular adhesion. Many of these functions appear to be modulated by integrins, and there is a growing body of evidence suggesting that variations in expression of these molecules can have a profound effect upon tumour biology (Albelda, 1993) .
Integrins include a diverse family of heterodimeric cell surface receptors for constituents of the extracellular matrix (ECM) and occasionally for other cell-associated adhesion molecules (Hynes, 1987) . They are composed of non-covalently associated a-and ,-glycoprotein subunits, and receptor diversity and ligand specificity are generated by the various associations of at least eight known n-subunits and 14 a-subunits.
In recent years, it has become apparent that integrins do not function merely as transmembrane rivets, linking the cell to the ECM, but that they are also involved in signalling (Hynes, 1992) . In this way, the extracellular environment can influence cellular activity during functions as diverse as migration, differentiation and cell survival.
In the present study we have examined the expression and function of the av-containing heterodimers in a panel of breast cancer cell lines. The av subunit has been shown to dimerize with a variety of ,-subunits, including PI, j83, P5, ,36 and P8 and, with the exception of avp6, all these heterodimers have been shown to composition of the av-containing heterodimers can affect cell behaviour by determining adhesive interactions. The nature of the vitronectin receptor is of particular interest in oncology because it has been implicated in tumour progression and acquisition of invasiveness (Marshall and Hart, 1996) . In melanoma, for example, the expression of avP3 correlates with invasiveness (Gehlsen et al, 1992) and there is a correlation between avP3 and tumorigenic capacity (Marshall et al, 1991; Marshall and Hart, 1996) . Recently, there has been evidence of a close functional inter-relationship between members of the av subfamily and the uPA/uPAR proteolytic system (Nip et al, 1995; Stefansson and Lawrence, 1996; Yebra et al, 1996) . This is of particular interest in breast cancer in which uPA (Duffy et al, 1990 ) and uPAR expression have been shown to correlate with prognosis (Duggan et al, 1995) . Accordingly, as a first step in elucidating the role of vitronectin receptors in breast cancer, it seemed important to examine the composition and function of putative vitronectin receptors, i.e. av-containing heterodimers, in breast cancer cells. We have used fluorocytometry, immunoprecipitation and indirect immunofluorescence to examine the expression of ocv integrins in a panel of breast cancer cell lines and identified the dominant vitronectin receptor by performing adhesion assays with function-blocking antibodies.
MATERIALS AND METHODS Cell lines and tissue culture
All cell lines were obtained from the Central Cell Services at the Imperial Cancer Research Fund. Eight human breast cancer cell lines were used in this study and were cultured in the following media supplemented with 10% fetal calf serum (FCS) (GIBCO BRL, Paisley, UK) and L-glutamine 4 mm. Lines ZR75-1, MDA-MB-231 and MDA-MB 468 were grown in Eagle's minimal essential medium (EMEM). Lines T47D and BT474 were grown in Roswell Park Memorial Institute medium (RPMI-1640) supplemented with (Soule et al, 1990 ). This was cultured in a 1:1 mixture of EMEM and Ham's F12 medium supplemented with 5% horse serum (GIBCO), 20 ng ml-' epidermal growth factor (Sigma), 10 gg ml-1 insulin, 5 mg ml-' hydrocortisone and 100 ng ml-1 cholera toxin (Sigma). DX3 is a human melanoma cell line used as a positive control in some experiments and this was cultured in EMEM with 10% FCS and L-glutamine. All cells were grown as monolayers on plastic at 37°C in a humidified atmosphere of 8% carbon dioxide-92% air. Cells were subcultured at 70-90% confluency using trypsin 0.25% (w/v)/ EDTA 5 mM to detach cells.
Antibodies
The following mouse monoclonal antibodies were used -anti-xv: P2W7 (produced in-house), 17E6 (function blocking; a gift from Dr SL Goodman, E Merck, Germany), L230 (ATCC); anti-p1: Ninety-six-well plates were coated with vitronectin at a concentration of 5 9g ml-'. 5'Cr-labelled cells suspended in serum-free medium were plated into the wells and incubated for 1 h at 370C. 
Immunoprecipitation and immunodepletion
Cells were detached using trypsin/EDTA, washed and resuspended in cold PBSA to a maximum concentration of 107 cells ml'. Cell surface proteins were then labelled with 1251 using the lactoperoxidase method (Marshall et al, 1991) . Cells were then lysed in ice-cold 1% NP40 buffer at I07 cells ml-1 (20 mm HEPES pH 7.8,1% NP40, 50 mm sodium chloride, 1 mM calcium chloride, 3 mm magnesium chloride, 0.3 M sucrose, 0.1% sodium azide) to which the protease inhibitors leupeptin (100 gg ml-'), phenylmethylsulphonyl fluoride (100 ,ug ml-'), aprotinin (100 ,ug ml-') and benzamidine (10 mM) were added. Cellular debris was removed by centrifugation and TCA precipitation performed to equilibrate the c.p.m. per volume between samples. This allowed equal amounts of labelled membrane protein to be loaded into each lane.
Lysates were then incubated on ice with mouse primary antibody (neat supernatant or purified at 1-20 mg ml' final concentration) for 15 min followed by 10 ml of rabbit anti-mouse IgG (Dako) for 10 min and finally 50 ml of protein A-Sepharose (Pharmacia, Milton Keynes, UK; 50% suspension with NP40 Lysis buffer). This mixture was tumbled overnight at 4°C and the precipitated complexes washed with a series of high-salt or high-detergent wash buffers to reduce non-specific binding (Marshall et al, 1991) .
Immunoprecipitates were run on a 6% SDS-PAGE gel under nonreducing conditions, and the gel was dried and autoradiographed.
In immunodepletion experiments, four immunoprecipitation cycles were performed with one primary antibody before immunoprecipitating with a second primary antibody.
Adhesion assays
The wells of 96-well plates (Falcon 3912; Beckton Dickinson, NJ, USA) were coated with vitronectin (Life Technologies or Combined Biomedical Products) at a concentration of 5 gg ml-' in PBSA and incubated for 90 min at 37°C or overnight at 4°C. The plates were then washed twice with PBSA and flooded with PBSA containing 0.1% BSA to block residual binding sites and incubated at 37°C for a further 60 min.
Cells were detached with trypsin/EDTA, resuspended in complete medium and labelled with 5lCr (Marshall et al, 1991) . After washing three times in serum-free medium, the cells were added to quadruplicate wells (50-,ul aliquots; 2 x 104 cells). In the inhibition of adhesion assays, 25 jl of antibodies (diluted to 1:50) were added to the wells.
The antibody-cell mixture was followed by 25-,ul volumes of cell suspension containing 2 x 104 cells allowed to sit on ice for 10 min before proceeding with the assay cells. The plates were then incubated at 37°C for 60 min and unbound cells were removed by immersion and agitation in PBSA twice. Individual wells were then separated and bound radioactivity counted using a gamma counter (1261 Multigamma; LKB Wallace, Bromma, Sweden.) Input radioactivity was measured using reserved 50-,ul aliquots of labelled cells, and background binding was measured by incubating cells in uncoated wells that had been blocked with the BSA solution only.
Immunofluorescence
Sterile 13-mm coverslips were placed in the wells of a 24-well plate; 500 gl of cell suspension (2 x 105 cells ml-') was added to the wells and incubated at 37°C. Morphology of the cells on the different substrates was examined by precoating the coverslips with various ECM proteins and adding the cells in a serum-free medium.
At certain time intervals thereafter, the coverslips were washed with 0.1% BSA in phosphate-suffered saline (PBS) and fixed in 1:10 formalin for 1O min. Cells were then incubated in 0.1% Triton X for 10 min and incubated with the primary antibody at 4'C for 45 min. They were then washed and incubated with FITC-labelled rabbit anti-mouse antibody. After further washing, the coverslips were mounted onto glass slides and examined with a fluorescence microscope (Zeiss Axioplan, Zeiss Microscopes, Welwyn Garden City, UK).
RESULTS

Fluorocytometry
The surface expression of av-containing heterodimers was analysed by fluorocytometry. 
Immunoprecipitation
Breast cell lines were surface labelled with 1251, lysed and immunoprecipitated with L230 (anti-av) as the primary antibody. Figure  1A shows the results of such an immunoprecipitation. The need to expose the film long enough to detect signal from the cells expressing lowest levels of these molecules has led to substantial overexpression of such strongly positive cells as the BT20 and MCF7 cell lines. However, it can be seen that, in six of the eight breast cancer cell lines, at least two other proteins are co-immunoprecipitated. The size of the upper band corresponds to that of the axv subunit, while the middle band runs at the same rate predicted for the [1 subunit. The lower bands correspond in electrophoretic mobility to that expected from other [-subunits, including [3, [5, [6 and 18. In this experiment, the [31 is not clearly seen in the SKBR3 or BT474 lanes, suggesting that it is only weakly expressed in these cells. The normal breast cell line MCF1OA expresses high levels of av, but again the [1 band is relatively weak.
That class-matched control antibody MEC 13.3. The cleared lysates were then immunoprecipitated with P2W7 (anti-av). It is clear from the illustration that, while the upper (ocv) band and lower bands are of equivalent intensity, the signal for the middle band has been reduced significantly by pre-clearing the 5l integrins with MAR4 relative to the three bands observable in the MEC 13.3-cleared lysates (Figure lB) . This provides strong immunological evidence that the middle band indeed is P1.
These data, together with the FACS data, indicate that av35 is expressed on all epithelial breast cancer cell lines examined and that cxvjl is expressed on the majority.
Adhesion to vitronectin
The classical vitronectin receptor acvP3 is not expressed by the majority of breast cancer cells, although both ocvP5 and cxvpl1, which have been reported as mediating vitronectin binding (Cheresh et al, 1989; Bodary and McLean, 1990) , are expressed by these cells. Adhesion assays were performed to ascertain the identity of the dominant vitronectin receptor.
In Figure 2 representative examples of adhesion assays on vitronectin substrates are shown. All the breast cancer cell lines bound to vitronectin with between 20% and 70% of added cells adhering within the time span of the experiment. The 'normal' MCFIOA cell line bound most poorly, with fewer than 10% of added cells adhering over the 60-min period of the assay. In all breast cancer cell lines examined, with the exception of BT20, adhesion was reduced significantly by the presence of the oxvblocking antibody 17E6 (Figure 2) . In all cases, except ZR75-1, a similar degree of inhibition was achieved using the avP5-blocking antibody P1 F6. For ZR75-1 cells, the 11-blocking antibody P4C 10 was required in addition to P1 F6 to achieve equivalent inhibition to that achieved with 17E6 alone. It seems, therefore, that the dominant vitronectin receptor in these tumour cells is cxvI35, although (Xvl1 appears to contribute significantly to this binding activity in ZR75-1 cells. The adhesion of BT20 to vitronectin is not significantly diminished by the antibodies used, raising the possibility of alternative receptors. It is notable that other non-integrin receptors, such as uPAR, have been shown to bind to vitronectin in some cells (Wei et al, 1994) , and this may be relevant here. MCF1OA binds very weakly to vitronectin (8.2% adhesion to vitronectin compared with 4.2% adhesion to BSA; P = 0.05, Mann-Whitney test), even though it expresses avP5 albeit at low levels. The addition of 1 mM Mn2 , which is known to activate integrins, increases adhesion two-to threefold, and this increase can be inhibited by 17E6 (data not shown). Variation in the relative activation status of these receptors in different cell lines may explain why there is no clear correlation between the level of integrin expression and the level of adhesion.
Distrubution of integrin subunits in cells adherent to vitronectin The pattern of integrin expression in response to vitronectin was examined by indirect immunofluoresence. Coverslips were precoated with vitronectin at a concentration of 5,g ml-'. Cells were incubated at 37°C for 4-24 h and labelled with primary antibodies directed against various integrin subunits. A fluoresceinconjugated secondary antibody was then used to visualize integrin distribution. In several cell lines a distinct pattern was seen. Figure  3 shows MCF7 and ZR75-1 cells plated on vitronectin and then labelled for xv and PI. These subunits are distributed in focal plaques suggesting that, in addition to mediating adhesion and spreading, they may be involved in signalling. The ,1 integrin in PI-positive focal adhesions on vitronectin is probably av,Bl, although the absence of a heterodimer-specific reagent for this integrin rules out definitive confirmation. However, apart from avfl, the only other cxJl integrin reported to bind vitronectin is a81I (Schnapp et al, 1995) . Antibodies to a8 were not available for this study. However, as blocking av with 17E6 abrogated adhesion of ZR75-1 and MCF7 to vitronectin, 08S1, if present, is unlikely to contribute to adhesion on vitronectin. In contrast, blocking both avP5 and f1 resulted in a greater inhibition of adhesion to vitronectin than blocking avP5 alone (Figure 2 ), suggesting that a PI integrin also contributes, albeit weakly, to vitronectin adhesion in breast carcinoma cells.
The avP5 heterodimer may also contribute to the av plaques, although we were unable to confirm this using P1F6 as the primary antibody because of poor staining.
The adhesion assays clearly show avP5 to be the major receptor mediating adhesion to vitronectin, yet the immunofluoresence suggests that avpl is responding to vitronectin and possibly initiating signals in the absence of strong adhesion.
DISCUSSION
We have shown in the present studies that the classical vitronectin receptor exvP3 is expressed in only one of the eight breast cancer cell lines examined. Rather, the major vitronectin receptor in this neoplastic cell type is the avP5 heterodimer, which is expressed by all cells and is generally responsible for adhesion to vitronectin.
The axvpl heterodimer is expressed by most tumour cells examined but relatively weakly expressed in the only normal breast cell line, MCF1OA, used in these studies.
Several immunohistochemical studies have examined the expression of integrins in breast cancer compared with that in normal breast tissue. (D'Ardenne et al, 199 1; Koukoulis et al, 199 1; Pignatelli et al, 1992) . The overall impression from these diverse reports is that the expression of most subunits is down-regulated. One exception to this is the av subunit, whose expression appeared to be increased in at least one study (Pignatelli et al, 1992 ). This did not correspond to an increased expression in av133, implying that another av-containing heterodimer(s) may be associated with this cancer type. The shortcomings of these immunohistochemical studies are that these data frequently refer to the presence of integrin subunits rather than heterodimers, and no inference can be made regarding the functional status of the receptors.
A recent study using colorectal cancer cell lines also found avP5 to be expressed by all neoplastic cells studied with variable expression of av,B3 and av13l levels (Agrez et al, 1996) . No functional analysis was performed in this report but it may be that av135 is the dominant vitronectin receptor in cells of epithelial lineage. This is in marked contrast to stromal and endothelial cells that express av133. The fact that this has not been reported widely is probably indicative of the relative paucity of studies using epithelial cell lines to examine the mechanics of cell adhesion.
Although avP5 mediates adhesion to vitronectin, these cells do not migrate on vitronectin in serum-free medium (unpublished observations). Recently, it was reported that the migration of MCF7 cells on vitronectin can be induced by insulin-like growth factor type 1 and that this can be blocked with the addition of PlF6 (anti-av,B5) (Doerr and Jones, 1996) . This suggests that the expression of av135 by epithelial cells is necessary but not sufficient for motility. Interestingly, in a human pancreatic cell line, Yebra et al (1996) have shown recently that avP5-mediated migration on vitronectin requires the presence of receptor-bound urokinase-type plasminogen activator (uPA), which itself is induced by transforming growth factor alpha (TGF-x) or phorbol ester. It will be of interest to see whether a similar relationship exists in breast cancer cells in the light of our categorization of the nature of the vitronectin receptor and the importance of uPA as a prognostic factor in breast cancer. We have also demonstrated the apparent ubiquity of av13l expression in breast cancer cells. The ligand specificity of this receptor seems to vary depending on the cell type. In malignant melanoma (Marshall et al, 1995) and human embryonic kidney cells (Bodary and McLean, 1990) , it mediates adhesion to vitronectin whereas, in neuroblastoma cells, fibroblasts and glioblastoma cells, it appears to mediate adhesion to fibronectin (Vogel et al, 1990) . In breast cancer it does not appear to contribute to vitronectin binding, except perhaps in ZR75-1 cells. The absence of a monoclonal antibody to this heterodimeric receptor hampers its further study, particularly in immunohistochemistry. Gui and colleagues (Gui et al, 1995) did report the loss of av13l with lymph node metastasis in mammary carcinoma, but this was inferred from subunit density and may not represent the true expression of the heterodimer as 11 is a component of many different heterodimers. Our own observation that Xvp l expression is very weak or possibly lacking in MCF1OA is intriguing not only because it is the only 'normal' cell line examined but also because it manifestly expresses both the (xv and 1P subunits in abundance.
Why these subunits associate in some but not other cell types is unclear. Certainly further work needs to be done on this receptor to understand what governs its expression and to identify its ligand specificity and function in breast cancer.
